Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company's revenue for the first half of 2025 was 1.73 billion, with a net profit of 240 million, reflecting a year-on-year growth of 7.9% in revenue but a decline of 13.4% in net profit due to increased expense ratios and decreased other income, primarily impacted by DTC transformation compensation costs [2] - The company declared an interim dividend of HKD 0.11 per share and a special interim dividend of HKD 0.05 per share, resulting in an annual dividend yield of 8.2% [2] Summary by Sections Revenue and Profitability - In the first half of 2025, the main brand and light business series revenues were 1.19 billion and 537 million respectively, with year-on-year growth of -0.2% and 31.8% [3] - The gross margin for the first half of 2025 was 50.2%, an increase of 0.2 percentage points, while the operating profit margin (OPM) decreased by 4.5 percentage points to 15.1% [4] Cash Flow and Inventory - The operating cash flow for the first half of 2025 was 118 million, a decline of 46.61% year-on-year, primarily due to increased inventory and accounts receivable [2][4] - Inventory turnover days increased to 231 days, up by 42 days year-on-year, with inventory rising by 30.5% to 1.084 billion [4] Store Expansion and Retail Strategy - The company plans to open 50-100 new stores in the second half of 2025, focusing on transitioning from consignment to direct sales and enhancing its new retail strategy [5][6] - As of the first half of 2025, the company had 2,774 stores, a 2.4% increase year-on-year, with a significant growth in online new retail sales by 24.6% [3] Future Outlook - The company is optimistic about the growth potential of its light business series, e-commerce channels, and international expansion, with the first overseas store opened in Malaysia [5][6] - Revenue forecasts for 2025-2027 have been adjusted downwards, with expected revenues of 40.16 billion, 44.39 billion, and 49.03 billion respectively [6]

Major Events - QianShi International (00381) subsidiary FuLao Investment signed a memorandum of understanding with Yanji Municipal Government for potential cooperation in digital economy-related businesses in Hong Kong [1] - Stone Pharmaceutical Group (02005) obtained production registration approval for potassium chloride and sodium chloride injection (500ml and 250ml) [1] - Basilea Pharmaceutica (02616) received approval from the National Medical Products Administration for the domestic production registration application of Prujita® (Pralsetinib capsules) [1] - United BioPharma (03933) received FDA approval for new drug clinical trials for UBT37034 injection [1] - China National Pharmaceutical Group (01177) had the application for the new indication of Kumosil capsules for first-line treatment of breast cancer accepted [1] - Oceanwide Holdings (08476) applied to the Stock Exchange for a transfer listing to the main board [1] Financial Data - Kaison Holdings (00102) reported a loss attributable to shareholders of approximately HKD 740 million for 2023, a shift from profit to loss year-on-year [1] - JiaoGe Friends Holdings (01450) achieved a cumulative GMV of approximately CNY 6.98 billion in the first half of the year, a year-on-year increase of approximately 17.11% [1] - Sunny Optical Technology (02382) reported a smartphone lens shipment of approximately 95.056 million units in June, a month-on-month decrease of 3.1% and a year-on-year decrease of 12.7% [1] - Fast Retailing (06288) announced a profit attributable to the parent company of JPY 339.099 billion for the first three quarters, a year-on-year increase of 8.4% [1] - Jianye Real Estate (00832) reported a total property contract sales of CNY 4.44 billion in the first half of the year, a year-on-year decrease of 1.2% [1] - China Lilang (01234) reported a mid-to-high single-digit year-on-year growth in retail sales of "LILANZ" products in the first half of the year [1]